Cantor Fitzgerald Reiterates Overweight on Cidara Therapeutics, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Cidara Therapeutics (NASDAQ:CDTX) and maintained a $5 price target.
August 01, 2023 | 2:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Cidara Therapeutics and maintained a $5 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Cidara Therapeutics. The maintained price target of $5 also suggests that the analyst believes the stock is undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100